title: Neonatal conjunctivitis: a profile.
abstract: Neonatal conjunctivitis is one of the commonest infections encountered in the newborn. A prospective study was conducted on all babies born over a period of one year. No prophylactic ocular medication was instilled routinely in newborns. Babies developing purulent eye discharge were diagnosed to have conjunctivitis. Eye Swab from the neonates and maternal vaginal/cervical swabs were sent for culture. Chloromycetin eye drops were used for treatment and in case of no response, changed as per sensitivity report or to gentamicin eye drops. Oral erthromycin was given for dacryocystitis or when there was no response to topical therapy. The incidence of conjunctivitis was 7.2%. Two seasonal peaks, namely, February and then May and June, were noted. In 91.6% of the babies, conjunctivitis developed within the first week. A prolonged rupture of membranes was associated with a significantly higher incidence of conjunctivitis (p < 0.01). The most common organism grown from conjunctival swab was Staph aureus (35.2%) followed by Enterococcus (4.3%), Klebsiella (3.5%) and E. coli (2.8%). From vaginal/cervical swabs, E. coli was the most common organism isolated. No concurrence of organisms was noted between eye swabs and vaginal/cervical swabs. A uniformly good response to chloromycetin eye drops was noted with only 3.5% requiring a change of therapy. It is concluded that neonatal conjunctivitis is commonly acquired postnatally and responds well to topical chloromycetin therapy. Oral erythromycin may be used in resistant cases which will cover the chlamydial infection also.
authors.affiliation: Department of Pediatrics, Christian Medical College, Ludhiana.
authors.forename: M
authors.initials: M
authors.lastname: Verma
authors.forename: J
authors.initials: J
authors.lastname: Chhatwal
authors.forename: P V
authors.initials: PV
authors.lastname: Varughese
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003234:Conjunctivitis, Bacterial / Q000151:congenital* / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents